Showing results (131-140 of 157) with videos related to
Sort By:
Pageof 16
Oncotarget|June 19, 2015
Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signalingAnja Heinemann, Carleen Cullinane, Ricardo De Paoli-Iseppi, et al.International Journal of Rheumatic Diseases|May 9, 2017
Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysisAnna J Lomax, Helen M McGuire, Catriona McNeil, et al.Nature Communications|August 26, 2018
SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signallingThomas Strub, Flavia G Ghiraldini, Saul Carcamo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanomaMalcolm Ranson, Peter Hersey, Damien Thompson, et al.Oncotarget|August 26, 2015
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesJessamy C Tiffen, Dilini Gunatilake, Stuart J Gallagher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanomaAxel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.The Journal of Investigative Dermatology|August 31, 2012
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanomaGraham J Mann, Gulietta M Pupo, Anna E Campain, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung CancerBenjamin Dizier, Andrea Callegaro, Muriel Debois, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 TreatmentJarem Edwards, James S Wilmott, Jason Madore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic MelanomaCaroline Robert, Antoni Ribas, Omid Hamid, et al.Pageof 16